| Identification | Back Directory | [Name]
PAR-4 Agonist Peptide, amide TFA | [CAS]
1228078-65-6 | [Synonyms]
AY-NH2 TFA)
PAR-4-AP (TFA)
PAR-4 Agonist Peptide, amide TFA
PAR-4 Agonist Peptide, amide TFA (PAR-4-AP TFA | [Molecular Formula]
C??H??F?N?O? | [MOL File]
1228078-65-6.mol | [Molecular Weight]
794.83 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 250 mg/mL (314.54 mM) | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
H2O: >10mg/mL | [Sequence]
H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2 |
| Hazard Information | Back Directory | [Uses]
4-Androsten-11β-ol-3,17-dione has been used in platelet aggregation.', 'AYPGKF- NH2 may be used for probing PAR4 signaling in culture systems and in platelets. | [Biological Activity]
AYPGK is a ligand for the PAR4 receptor; binding results in activation of PAR4. AYPGK stimulates platelet aggregation in vitro (EC50 =15 μM) via PAR4. In human platelets treated with the PAR4 agonistAYPGKF stimulates the production of thromboxanea potent agent for platelet-aggregation. AdditionallyAYPGKF mediates the thrombin-induced release of endostatin from r at platelets. | [in vivo]
Compared with their BALB/cBy controls, SCID mice have a significantly greater abdominal response to colorectal distension (CRD) at the distension levels of 0.04 to 0.1 mL increasing the intensity of EMG response by 384% to 132%, respectively (P<0.01; P<0.01; P<0.01; P<0.001). PAR-4 activation effectively reverses this hypersensitivity (P<0.01, P<0.05; P<0.05; P<0.05)[1]. |
|
|